A citation-based method for searching scientific literature

Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding, Marc S Sabatine. Lancet 2019
Times Cited: 856







List of co-cited articles
511 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Empagliflozin's Fuel Hypothesis: Not so Soon.
Gary D Lopaschuk, Subodh Verma. Cell Metab 2016
81
3

Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease.
Ben A Kappel, Michael Lehrke, Katharina Schütt, Anna Artati, Jerzy Adamski, Corinna Lebherz, Nikolaus Marx. Circulation 2017
52
5

Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging.
Kengo Kidokoro, David Z I Cherney, Andrea Bozovic, Hajime Nagasu, Minoru Satoh, Eiichiro Kanda, Tamaki Sasaki, Naoki Kashihara. Circulation 2019
73
4


Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure.
Kenneth C Bedi, Nathaniel W Snyder, Jeffrey Brandimarto, Moez Aziz, Clementina Mesaros, Andrew J Worth, Linda L Wang, Ali Javaheri, Ian A Blair, Kenneth B Margulies,[...]. Circulation 2016
214
3


Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.
Rena R Wing, Paula Bolin, Frederick L Brancati, George A Bray, Jeanne M Clark, Mace Coday, Richard S Crow, Jeffrey M Curtis, Caitlin M Egan, Mark A Espeland,[...]. N Engl J Med 2013
3

Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.
Ralph A DeFronzo, Luke Norton, Muhammad Abdul-Ghani. Nat Rev Nephrol 2017
185
3


Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?
Silvio E Inzucchi, David Fitchett, Dubravka Jurišić-Eržen, Vincent Woo, Stefan Hantel, Christina Janista, Stefan Kaspers, Jyothis T George, Bernard Zinman. Diabetes Obes Metab 2020
26
11

Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes.
Eberhard Standl, Oliver Schnell, Darren K McGuire. Circ Res 2016
36
8

2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
Sandeep R Das, Brendan M Everett, Kim K Birtcher, Jenifer M Brown, William T Cefalu, James L Januzzi, Rita Rastogi Kalyani, Mikhail Kosiborod, Melissa L Magwire, Pamela B Morris,[...]. J Am Coll Cardiol 2018
159
3

The Serendipitous Story of SGLT2 Inhibitors in Heart Failure.
Subodh Verma, John J V McMurray. Circulation 2019
23
13



Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.
Bernhard Ludvik, Juan P Frías, Francisco J Tinahones, Julio Wainstein, Honghua Jiang, Kenneth E Robertson, Luis-Emilio García-Pérez, D Bradley Woodward, Zvonko Milicevic. Lancet Diabetes Endocrinol 2018
101
3

Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
Elisabetta Patorno, Ajinkya Pawar, Jessica M Franklin, Mehdi Najafzadeh, Anouk Déruaz-Luyet, Kimberly G Brodovicz, Steven Sambevski, Lily G Bessette, Adrian J Santiago Ortiz, Martin Kulldorff,[...]. Circulation 2019
72
4

Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials.
Jacob A Udell, Matthew A Cavender, Deepak L Bhatt, Saurav Chatterjee, Michael E Farkouh, Benjamin M Scirica. Lancet Diabetes Endocrinol 2015
159
3

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials.
Kausik K Ray, Sreenivasa Rao Kondapally Seshasai, Shanelle Wijesuriya, Rupa Sivakumaran, Sarah Nethercott, David Preiss, Sebhat Erqou, Naveed Sattar. Lancet 2009
844
3


Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.
Kunihiro Matsushita, Marije van der Velde, Brad C Astor, Mark Woodward, Andrew S Levey, Paul E de Jong, Josef Coresh, Ron T Gansevoort. Lancet 2010
3

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.
Alan S Go, Glenn M Chertow, Dongjie Fan, Charles E McCulloch, Chi-yuan Hsu. N Engl J Med 2004
3

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
David C Wheeler, Bergur V Stefansson, Mikhail Batiushin, Oleksandr Bilchenko, David Z I Cherney, Glenn M Chertow, Walter Douthat, Jamie P Dwyer, Elizabeth Escudero, Roberto Pecoits-Filho,[...]. Nephrol Dial Transplant 2020
17
17


Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.
Gianluigi Savarese, Naveed Sattar, James Januzzi, Subodh Verma, Lars H Lund, David Fitchett, Cordula Zeller, Jyothis T George, Martina Brueckmann, Anne Pernille Ofstad,[...]. Circulation 2019
22
13

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
340
3

Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus.
Kristina Striepe, Agnes Jumar, Christian Ott, Marina V Karg, Markus P Schneider, Dennis Kannenkeril, Roland E Schmieder. Circulation 2017
49
6


Canagliflozin Improves the Recovery of Blood Flow in an Experimental Model of Severe Limb Ischemia.
Stephen E Sherman, Gillian I Bell, Hwee Teoh, Mohammed Al-Omran, Kim A Connelly, Deepak L Bhatt, David A Hess, Subodh Verma. JACC Basic Transl Sci 2018
14
21

The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial.
Erika Opingari, Subodh Verma, Kim A Connelly, Cyril David Mazer, Hwee Teoh, Adrian Quan, Fei Zuo, Yi Pan, Deepak L Bhatt, Bernard Zinman,[...]. Nephrol Dial Transplant 2020
7
42

SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects.
Carolyn S P Lam, Chanchal Chandramouli, Vineeta Ahooja, Subodh Verma. J Am Heart Assoc 2019
45
6

Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis.
Muhammad Shariq Usman, Tariq Jamal Siddiqi, Muhammad Mustafa Memon, Muhammad Shahzeb Khan, Wasiq Faraz Rawasia, Muhammad Talha Ayub, Jayakumar Sreenivasan, Yasmeen Golzar. Eur J Prev Cardiol 2018
51
5


Basal insulin and cardiovascular and other outcomes in dysglycemia.
Hertzel C Gerstein, Jackie Bosch, Gilles R Dagenais, Rafael Díaz, Hyejung Jung, Aldo P Maggioni, Janice Pogue, Jeffrey Probstfield, Ambady Ramachandran, Matthew C Riddle,[...]. N Engl J Med 2012
965
3

PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial.
Martin Huelsmann, Stephanie Neuhold, Michael Resl, Guido Strunk, Helmut Brath, Claudia Francesconi, Christopher Adlbrecht, Rudolf Prager, Anton Luger, Richard Pacher,[...]. J Am Coll Cardiol 2013
134
3

Plasma natriuretic peptide levels and the risk of cardiovascular events and death.
Thomas J Wang, Martin G Larson, Daniel Levy, Emelia J Benjamin, Eric P Leip, Torbjorn Omland, Philip A Wolf, Ramachandran S Vasan. N Engl J Med 2004
3

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits.
Antonius Baartscheer, Cees A Schumacher, Rob C I Wüst, Jan W T Fiolet, Ger J M Stienen, Ruben Coronel, Coert J Zuurbier. Diabetologia 2017
224
3

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
Scott D Solomon, John J V McMurray, Inder S Anand, Junbo Ge, Carolyn S P Lam, Aldo P Maggioni, Felipe Martinez, Milton Packer, Marc A Pfeffer, Burkert Pieske,[...]. N Engl J Med 2019
415
3

Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes.
Franco Cosmi, Li Shen, Michela Magnoli, William T Abraham, Inder S Anand, John G Cleland, Jay N Cohn, Deborah Cosmi, Giorgia De Berardis, Kenneth Dickstein,[...]. Eur J Heart Fail 2018
48
6

Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, João Pedro Ferreira, Stuart J Pocock, Peter Carson, Inder Anand, Wolfram Doehner, Markus Haass,[...]. Circulation 2021
17
17

Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis.
Cai-Yan Zou, Xue-Kui Liu, Yi-Quan Sang, Ben Wang, Jun Liang. Medicine (Baltimore) 2019
20
15



Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: A propensity-matched cohort study.
Sruthi Adimadhyam, Todd A Lee, Gregory S Calip, Daphne E Smith Marsh, Brian T Layden, Glen T Schumock. Diabetes Obes Metab 2018
28
10

Role of diabetes in congestive heart failure: the Framingham study.
W B Kannel, M Hjortland, W P Castelli. Am J Cardiol 1974
3

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Deepak L Bhatt, P Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz,[...]. N Engl J Med 2019
878
3

Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy.
Anja Schork, Janine Saynisch, Andreas Vosseler, Benjamin Assad Jaghutriz, Nils Heyne, Andreas Peter, Hans-Ulrich Häring, Norbert Stefan, Andreas Fritsche, Ferruh Artunc. Cardiovasc Diabetol 2019
52
5

Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.
Jean-Claude Tardif, Simon Kouz, David D Waters, Olivier F Bertrand, Rafael Diaz, Aldo P Maggioni, Fausto J Pinto, Reda Ibrahim, Habib Gamra, Ghassan S Kiwan,[...]. N Engl J Med 2019
485
3

Colchicine in Patients with Chronic Coronary Disease.
Stefan M Nidorf, Aernoud T L Fiolet, Arend Mosterd, John W Eikelboom, Astrid Schut, Tjerk S J Opstal, Salem H K The, Xiao-Fang Xu, Mark A Ireland, Timo Lenderink,[...]. N Engl J Med 2020
152
3

2018 ESC/ESH Guidelines for the management of arterial hypertension.
Bryan Williams, Giuseppe Mancia, Wilko Spiering, Enrico Agabiti Rosei, Michel Azizi, Michel Burnier, Denis L Clement, Antonio Coca, Giovanni de Simone, Anna Dominiczak,[...]. Eur Heart J 2018
3


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.